You are here:

  1. Home
  2. NICE Guidance
  3. Conditions and diseases
  4. Cancer
  5. Metastases

Sunitinib for the first-line treatment of advanced and/or metastatic renal cell carcinoma

  • Technology appraisal guidance
  • Reference number: TA169
  • Published:  25 March 2009
  • Guidance
  • Tools and resources
  • Information for the public
  • Evidence
  • History

Consultee and commentator comments on the extra work consultation

  • Bayer

  • British Uro-oncology Group

  • Novartis

  • Pfizer

  • Roche

  • Royal College of Nursing

  • Royal College of Physicians

  • Wyeth


This page was last updated: 30 March 2010

Back to top